Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Atezolizumab, Bevacizumab, and Chemotherapy for Patients with Advanced Cervical Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called cervical cancer, specifically when it has spread to other parts of the body (metastatic), is persistent, or has returned after treatment. The study is testing a combination of treatments to see if they can help patients live longer without the cancer getting worse. The treatments being tested include a chemotherapy drug called paclitaxel, combined with another drug called bevacizumab (also known as Avastin), and a third drug called atezolizumab (also known by its code name RO5541267 or Tecentriq). These drugs are given as a solution through a vein, which is known as an infusion.

The purpose of the study is to find out if adding atezolizumab to the usual treatment of chemotherapy and bevacizumab can improve the time patients live without their cancer getting worse and if it can help them live longer overall. Participants in the study will be randomly assigned to receive either the combination of paclitaxel, bevacizumab, and atezolizumab or just paclitaxel and bevacizumab. The study will last for a period of time, and participants will receive regular infusions of the drugs. Some participants may receive a placebo instead of atezolizumab to compare the effects of the treatment.

Throughout the study, participants will be monitored closely by healthcare professionals to track their progress and any side effects they may experience. The study aims to provide valuable information on whether the addition of atezolizumab can offer better outcomes for patients with metastatic, persistent, or recurrent cervical cancer. This research could potentially lead to new treatment options for this type of cancer in the future.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be randomly assigned to one of two treatment groups. This means you will either receive a combination of atezolizumab, bevacizumab, and chemotherapy, or a combination of bevacizumab and chemotherapy without atezolizumab.

  2. Step 2

    Treatment administration

    If you are in the group receiving atezolizumab, you will be given a dose of 1,200 mg. This medication is administered as a solution for infusion, which means it is given directly into your vein through an intravenous (IV) line.

    You will also receive bevacizumab at a dose of 25 mg/ml, also as a solution for infusion. The chemotherapy drugs, which may include cisplatin or carboplatin and paclitaxel, will be administered according to the specific schedule set by the study team.

    The frequency and duration of these treatments will be explained to you by the study team, and they will monitor your progress throughout the trial.

  3. Step 3

    Monitoring and follow-up

    Throughout the trial, your health and response to the treatment will be closely monitored. This includes regular check-ups, blood tests, and imaging studies to assess the progression of your condition.

    The study team will also monitor for any side effects or adverse reactions to the medications. It is important to report any new symptoms or concerns to the study team promptly.

  4. Step 4

    End of treatment

    At the end of the treatment period, you will have a final evaluation to assess the overall impact of the treatment on your condition.

    The study team will discuss the results with you and provide guidance on any further steps or treatments that may be necessary.

Who can join the trial?

24 criteria

  • Must be a female patient.
  • Must be 18 years of age or older.
  • Must have a diagnosis of metastatic (stage IVB), persistent, or recurrent cervical cancer that cannot be treated with surgery or radiation for a cure.
  • Must have adequate organ function:
    • Hemoglobin (a protein in red blood cells) level of at least 9 g/dL.
    • ANC (a type of white blood cell) of at least 1.5 x 109/L.
    • Lymphocyte count (another type of white blood cell) of at least 0.5 x 109/L.
    • Platelet count (cells that help with blood clotting) of at least 100 x 109/L.
    • Must have adequate liver function:
      • Serum albumin (a protein made by the liver) of at least 2.5 g/dL.
      • Total serum bilirubin (a substance made by the liver) of no more than 1.5 times the upper limit of normal (ULN).
      • AST and ALT (liver enzymes) of no more than 2.5 times ULN, or no more than 5 times ULN if the liver is affected by the tumor.
      • Must have adequate kidney function:
        • Serum creatinine (a waste product filtered by the kidneys) of less than 1.5 times ULN.
        • Urine dipstick for proteinuria (protein in urine) of less than 2+. If 2+ proteinuria is found, a 24-hour urine collection must show less than 1 g of protein in 24 hours or a urine protein/creatinine (UPC) ratio of 1.0 or less.
        • Must have adequate blood clotting:
          • INR (a measure of blood clotting) of 1.5 or less, or between 2 and 3 if on a stable dose of warfarin (a blood thinner).
          • PTT (another measure of blood clotting) of less than 1.5 times ULN.
          • Must have negative test results for Hepatitis.
          • Must have recovered from side effects of previous treatments to less than grade 2, except for hair loss.
          • Must be postmenopausal, surgically sterile, or have a negative pregnancy test and agree to use effective birth control during the study and for a period after the last dose of study treatment.
          • Must provide signed informed consent before any study-specific procedures.
          • Must be able to comply with the study protocol, as judged by the investigator.
          • Must have a GOG/ECOG performance status of 0-1, which means being fully active or restricted in physically strenuous activity but able to carry out light work.
          • Must have a life expectancy of at least 3 months.
          • Must have measurable disease by RECIST v1.1 criteria, which means having at least one "target lesion" to assess response to treatment. If the only target lesion is in a previously treated area, a biopsy is needed to confirm cancer.
          • Must provide a tumor specimen at study entry, which can be an old biopsy or a new one from a non-treated area within 3 months of starting the study.
          • Must not have had prior systemic anti-cancer therapy for metastatic or recurrent disease. Previous chemo-radiotherapy with curative intent must have been completed at least 3 months before joining the study. Palliative radiation therapy for symptoms like pain or bleeding is allowed if it was done 6 weeks before joining and does not affect measurable disease.

Who cannot join the trial?

10 criteria

  • Patients with other types of cancer besides the specific type being studied cannot participate.
  • Patients who have had a different cancer in the past, unless it was treated and has not come back for at least 5 years, cannot participate.
  • Patients who have an active infection that requires treatment with antibiotics cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have a serious heart condition, such as a recent heart attack or heart failure, cannot participate.
  • Patients who have a known allergy to any of the study drugs cannot participate.
  • Patients who have a condition that affects their immune system, such as HIV, cannot participate.
  • Patients who are currently participating in another clinical trial cannot participate.
  • Patients who have had a major surgery within the last 4 weeks cannot participate.
  • Patients who have a history of bleeding disorders cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Platinum Chemotherapy

    is a type of cancer treatment that uses drugs containing the metal platinum. These drugs work by damaging the DNA of cancer cells, which stops them from growing and dividing. In this trial, platinum chemotherapy is used to help treat cervical cancer that has spread, come back, or is not responding to other treatments.

  • Paclitaxel

    is a chemotherapy drug that helps stop cancer cells from growing by interfering with their ability to divide. It is often used in combination with other cancer treatments to improve their effectiveness. In this trial, paclitaxel is combined with other medications to treat advanced cervical cancer.

  • Bevacizumab

    is a medication that works by blocking a protein called VEGF, which helps tumors form new blood vessels. By stopping this process, bevacizumab can slow the growth of tumors and help shrink them. It is used in this trial to enhance the effects of chemotherapy in treating cervical cancer.

  • Atezolizumab

    is an immunotherapy drug that helps the body's immune system recognize and attack cancer cells. It works by blocking a protein that prevents the immune system from attacking cancer cells. In this trial, atezolizumab is added to the treatment plan to see if it can improve the outcomes for patients with advanced cervical cancer.

What is already known about the treatment

  • Bevacizumab

    Bevacizumab is administered through an intravenous infusion, meaning it is given directly into a vein. It is currently used in medicine to treat various types of cancer, including cervical cancer that has spread, returned, or is persistent. The main therapeutic indication for bevacizumab in this trial is to help improve survival rates when combined with chemotherapy. At the molecular level, bevacizumab works by blocking a protein called VEGF, which helps tumors grow new blood vessels, essentially starving the tumor of nutrients. It is classified as an angiogenesis inhibitor.

  • Atezolizumab

    Atezolizumab is also given through an intravenous infusion. It is an approved medication used in the treatment of certain cancers, and in this trial, it is being tested for its effectiveness in cervical cancer. The main therapeutic indication is to potentially improve survival rates when added to chemotherapy and bevacizumab. Atezolizumab works by blocking a protein called PD-L1, which helps the immune system recognize and attack cancer cells. It is classified as an immune checkpoint inhibitor.

Investigated diseases

Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix – This disease refers to a type of cancer that originates in the cervix and has spread to other parts of the body, or continues to exist despite treatment, or has returned after a period of remission. In its metastatic stage, the cancer cells have traveled beyond the cervix to distant organs, which can include the lungs, liver, or bones. Persistent carcinoma indicates that the cancer remains in the body even after initial treatment efforts. Recurrent carcinoma means the cancer has returned after being undetectable for a time. The progression of this disease involves the growth and spread of cancerous cells, which can lead to various symptoms depending on the organs affected. The disease can cause symptoms such as abnormal bleeding, pelvic pain, and changes in bladder or bowel habits as it advances.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-514179-17-00Protocol codeBEATccEstimated enrolment410 patientsSponsorFundacion Grupo Espanol De Investigacion En Cancer Ginecologico

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.